Aurobindo Pharma is trading higher by 3% to Rs 161 after the company said it has received tentative approval from the US Food & Drug Administration (USFDA) to manufacture and market anti-AIDS combination drug Efavirenz/ Emtricitabine and Tenofovir Disoproxil Fumarate Tablets.
“The company is one of the first generics firm to have received the tentative approval to manufacture and market its anti-AIDS combination drug Efavirenz / Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 600mg/200mg/300mg from the USFDA,” Aurobindo Pharma said in a BSE filing.
The drug is the generic equivalent of Gilead Sciences Inc’s Atripla® Tablets 600mg/200mg/300mg and falls under the Anti-Retroviral (ARV) segment, it added.
Meanwhile, the stock has outperformed the market by surging 24% in past four trading sessions on BSE after USFDA has lifted the import alert for Unit VI Cephalosporin facility, which allows company to resume the supply of 9 products to US market from the same unit. The benchmark Sensex has gained 1.5% during the same period.
The stock opened at Rs 157 and hit a high of Rs 163 on BSE. A combined 3.61 million shares have changed hands on the counter so far on BSE and NSE.
“The company is one of the first generics firm to have received the tentative approval to manufacture and market its anti-AIDS combination drug Efavirenz / Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 600mg/200mg/300mg from the USFDA,” Aurobindo Pharma said in a BSE filing.
The drug is the generic equivalent of Gilead Sciences Inc’s Atripla® Tablets 600mg/200mg/300mg and falls under the Anti-Retroviral (ARV) segment, it added.
Meanwhile, the stock has outperformed the market by surging 24% in past four trading sessions on BSE after USFDA has lifted the import alert for Unit VI Cephalosporin facility, which allows company to resume the supply of 9 products to US market from the same unit. The benchmark Sensex has gained 1.5% during the same period.
The stock opened at Rs 157 and hit a high of Rs 163 on BSE. A combined 3.61 million shares have changed hands on the counter so far on BSE and NSE.
